Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D
NCT05140694 on ClinicalTrials.gov · last registry update 2022-10-04
135 participants. Its estimated completion date, 30 June 2024, has passed with no update to the record. Primary outcome, as filed: Changes of HbA1c level. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. dulaglutide is approved in the US, but not for mash nafld — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- UNKNOWN
- Phase
- P4
- Drug
- dulaglutideTrulicity
- Sponsor
- Seoul National University Bundang Hospital
- Sponsor type
- Other
- Enrollment
- 135
- Started
- 2023-12-01
- Primary completion
- 2024-06-30 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Changes of HbA1c level
Conditions studied
Metabolic-associated Fatty Liver Disease · Type 2 Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.